Free Trial
NASDAQ:RNA

Avidity Biosciences Q1 2025 Earnings Report

Avidity Biosciences logo
$32.14 +0.13 (+0.41%)
As of 06/12/2025 04:00 PM Eastern

Avidity Biosciences EPS Results

Actual EPS
-$0.90
Consensus EPS
-$0.88
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Avidity Biosciences Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
$2.63 million
Beat/Miss
Missed by -$1.03 million
YoY Revenue Growth
N/A

Avidity Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Avidity Biosciences' Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Avidity Biosciences Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Analysts Offer Predictions for RNA FY2026 Earnings
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA), a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

View Avidity Biosciences Profile

More Earnings Resources from MarketBeat